Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc (CRVS) Expected Move
CRVS expected move through Nov 20, 2026 is 19.9%, with 3 days to expiration. The implied range is $8.49 to $12.71, based on the previous trading day's options prices.
Read more
Tracking the CRVS expected move helps you see how far Corvus Pharmaceuticals Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Corvus Pharmaceuticals Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the CRVS expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For CRVS, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The CRVS expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Corvus Pharmaceuticals Inc is unlikely to go.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the CRVS expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Corvus Pharmaceuticals Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about CRVS.
CRVS Price
Drag chart to pan. Drag axes to zoom.
| Expiration | DTE | Expected move (USD) | Expected move (%) | Upper price | Lower price |
|---|---|---|---|---|---|
| Nov 20, 2026 | 3 | $2.11 | 19.9% | $12.71 | $8.49 |
| Dec 18, 2026 | 31 | $3.13 | 29.5% | $13.73 | $7.48 |
| Jan 15, 2027 | 59 | $2.95 | 27.8% | $13.55 | $7.65 |
| Apr 16, 2027 | 150 | $4.93 | 46.5% | $15.52 | $5.68 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →